Medicine and Health

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

A. J. Sanyal, L. M. Kaplan, et al.

Retatrutide, a novel triple agonist, has shown remarkable efficacy in significantly reducing liver fat among participants suffering from metabolic dysfunction-associated steatotic liver disease. This 24-week study led by Arun J. Sanyal and colleagues highlights the potential transformative effects of this treatment, with reductions in liver fat reaching as high as 82.4%.

00:00

Playback language: English

Index

Abstract

Retatrutide, a triple agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, significantly reduced liver fat in a 24-week, randomized, double-blind, placebo-controlled trial (n=98) of participants with metabolic dysfunction-associated steatotic liver disease (MASLD). At 24 weeks, mean relative change from baseline in liver fat was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg), and +0.3% (placebo) (all *P* < 0.001 vs. placebo). Reductions were associated with changes in body weight, abdominal fat, and metabolic measures.

Publisher

Nature Medicine

Published On

Jul 01, 2024

Authors

Arun J. Sanyal, Lee M. Kaplan, Juan P. Frias, Bram Brouwers, Qiwei Wu, Melissa K. Thomas, Charles Harris, Nanette C. Schloot, Yu Du, Kieren J. Mather, Axel Haupt, Mark L. Hartman

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial

H. R. C. Shanks, K. Chen, et al.

Medicine and Health

Association between fast eating speed and metabolic dysfunction-associated steatotic liver disease: a multicenter cross-sectional study and meta-analysis

M. Zhang, X. Sun, et al.

Medicine and Health

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

A. H. Diacon, C. E. B. Iii, et al.

Medicine and Health

A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease

R. Cheng, L. Wang, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny